drugset / Trial / NCT07484074
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
Timeline
- Start
- 2025-02-12
- Primary completion
- 2025-10-10
- Completion
- 2025-12-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Faricimab | Monoclonal antibody | 6 mg | Intravitreal |
| Subject | OLN324 | Unknown | 2 mg | Intravitreal |
| Subject | OLN324 | Unknown | 4 mg | Intravitreal |